Audentes Therapeutics Company Profile (NASDAQ:BOLD)

About Audentes Therapeutics

Audentes Therapeutics logoAudentes Therapeutics, Inc. is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). AT132 is an Adeno-associated virus (AAV) 8 vector containing a functional copy of the MTM1 gene. The Company is engaged in developing AT342, which is an AAV8 vector, containing a functional version of the UGT1A1 gene. The AT982 uses an AAV serotype 9 capsid vector, containing a functional copy of the glucosidase alpha, acid (GAA) gene. The Company's principal operations are located in San Francisco, California.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BOLD
  • CUSIP:
Key Metrics:
  • Previous Close: $15.77
  • 50 Day Moving Average: $17.31
  • 200 Day Moving Average: $16.42
  • 52-Week Range: $13.06 - $20.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.11
  • P/E Growth: -1.66
  • Market Cap: $337.61M
  • Outstanding Shares: 21,725,000
Profitability:
  • Return on Assets: -41.00%
Debt:
  • Debt-to-Equity Ratio: -0.03%
  • Current Ratio: 12.35%
  • Quick Ratio: 12.35%
Additional Links:
Companies Related to Audentes Therapeutics:

Analyst Ratings

Consensus Ratings for Audentes Therapeutics (NASDAQ:BOLD) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.00 (41.66% upside)

Analysts' Ratings History for Audentes Therapeutics (NASDAQ:BOLD)
Show:
DateFirmActionRatingPrice TargetDetails
11/12/2016Piper Jaffray Cos.Set Price TargetBuy$24.00View Rating Details
9/1/2016WedbushReiterated RatingOutperform$20.00View Rating Details
8/15/2016Cowen and CompanyInitiated CoverageOutperformView Rating Details
(Data available from 1/19/2015 forward)

Earnings

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Audentes Therapeutics (NASDAQ:BOLD)
Current Year EPS Consensus Estimate: $-3.14 EPS
Next Year EPS Consensus Estimate: $-2.54 EPS

Dividends

Dividend History for Audentes Therapeutics (NASDAQ:BOLD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Audentes Therapeutics (NASDAQ:BOLD)
Institutional Ownership Percentage: 71.00%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2016James E FlynnInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
7/25/2016Orbimed Advisors LlcDirectorBuy33,334$15.00$500,010.00View SEC Filing  
7/25/2016Versant Ventures Iv, LlcMajor ShareholderBuy35,000$15.00$525,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Audentes Therapeutics (NASDAQ:BOLD)
DateHeadline
finance.yahoo.com logoAudentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance (NASDAQ:BOLD)
finance.yahoo.com - January 9 at 5:03 PM
finance.yahoo.com logo8:04 am Audentes Therapeutics's cash position is projected to fund operations into late 2018; provides FY17 milestones (NASDAQ:BOLD)
finance.yahoo.com - January 9 at 5:03 PM
finance.yahoo.com logoAudentes Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:BOLD)
finance.yahoo.com - January 4 at 4:57 PM
4-traders.com logoAudentes Therapeutics : Appoints Julie Anne Smith to Board of Directors (NASDAQ:BOLD)
www.4-traders.com - December 14 at 4:35 PM
4-traders.com logoAUDENTES THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K) (NASDAQ:BOLD)
www.4-traders.com - December 13 at 4:40 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:BOLD)
biz.yahoo.com - December 13 at 4:40 PM
insidermonkey.com logoHow Hedge Funds Played the Audentes Therapeutics Inc (BOLD) IPO (NASDAQ:BOLD)
www.insidermonkey.com - December 8 at 4:08 PM
4-traders.com logoAUDENTES THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:BOLD)
www.4-traders.com - November 30 at 5:43 AM
finance.yahoo.com logoAudentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility (NASDAQ:BOLD)
finance.yahoo.com - November 30 at 5:43 AM
finance.yahoo.com logoAudentes Therapeutics to Attend Piper Jaffray 28th Annual Healthcare Conference (NASDAQ:BOLD)
finance.yahoo.com - November 21 at 8:49 AM
fxpips.com logoThese Stocks are Making Gaps Up Before the Bell – WINS, NSPR, DGII, AYA, OBCI, EBIO, HAR (NASDAQ:BOLD)
www.fxpips.com - November 15 at 12:38 PM
marketexclusive.com logoAudentes Therapeutics, Inc. (NASDAQ:BOLD) Files An 8-K Reports Third Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:BOLD)
marketexclusive.com - November 14 at 3:28 PM
publicnow.com logoAudentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:BOLD)
www.publicnow.com - November 10 at 12:19 PM
bizjournals.com logoSupersized IPO charges up med device maker's first day (NASDAQ:BOLD)
www.bizjournals.com - October 21 at 12:12 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:BOLD)
biz.yahoo.com - September 28 at 8:59 AM
publicnow.com logoAudentes Therapeutics to Present at Upcoming Investor Conferences (NASDAQ:BOLD)
www.publicnow.com - September 21 at 8:28 AM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:BOLD)
biz.yahoo.com - September 2 at 8:38 AM
News IconAudentes Therapeutics Reports Second Quarter 2016 Financial Results and (NASDAQ:BOLD)
www.biomedreports.com - September 1 at 12:23 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (NASDAQ:BOLD)
biz.yahoo.com - September 1 at 12:23 PM
publicnow.com logoAudentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:BOLD)
www.publicnow.com - September 1 at 12:23 PM
bizjournals.com logoBay Area cosmetics company files for $100M IPO (NASDAQ:BOLD)
www.bizjournals.com - August 31 at 3:52 PM
wsj.com logo[$$] Biotech Investor Sofinnova Ventures Raises $595.5M Toward New Fund (NASDAQ:BOLD)
www.wsj.com - August 25 at 8:47 AM
streetinsider.com logoAudentes Therapeutics (BOLD) Enrolls First Patient in INCEPTUS Study of XLMTM (NASDAQ:BOLD)
www.streetinsider.com - August 18 at 12:20 PM
publicnow.com logoAudentes Therapeutics Announces First Patient Enrolled in the INCEPTUS Clinical Assessment Study of XLMTM (NASDAQ:BOLD)
www.publicnow.com - August 17 at 12:04 PM
finance.yahoo.com logoAudentes Therapeutics Initiated Overweight At Wedbush (NASDAQ:BOLD)
finance.yahoo.com - August 15 at 4:01 PM
finance.yahoo.com logoAudentes Therapeutics' Strong Pipeline Merits An Outperform Rating From Cowen And Company (NASDAQ:BOLD)
finance.yahoo.com - August 15 at 4:01 PM
finance.yahoo.com logoCoverage initiated on Audentes Therapeutics by Wedbush (NASDAQ:BOLD)
finance.yahoo.com - August 15 at 11:07 AM
publicnow.com logoAudentes Therapeutics Announces Pricing of Initial Public Offering (NASDAQ:BOLD)
www.publicnow.com - August 10 at 3:22 PM
finance.yahoo.com logoAudentes Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:BOLD)
finance.yahoo.com - August 8 at 8:43 AM
insidermonkey.com logoDeerfield Management Discloses Stake In Post-IPO Audentes Therapeutics (BOLD) (NASDAQ:BOLD)
www.insidermonkey.com - July 26 at 11:06 AM
247wallst.com logo4 IPOs on Calendar for Week of July 25 (NASDAQ:BOLD)
247wallst.com - July 24 at 10:55 AM

Social

Audentes Therapeutics (NASDAQ:BOLD) Chart for Thursday, January, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Earnings History Chart

Earnings by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Dividend History Chart

Dividend Payments by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Last Updated on 1/19/2017 by MarketBeat.com Staff